BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:04 PM
 | 
Aug 29, 2012
 |  BC Extra  |  Company News

ODAC cancels discussion of cabozantinib

Exelixis Inc. (NASDAQ:EXEL) said FDA told the company that cabozantinib will no longer be discussed at the Oncologic Drugs Advisory Committee (ODAC) meeting on Nov....

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >